Background
Transcatheter aortic valve implantation (TAVI) technology is currently evaluated in patients with severe aortic stenosis (AS) who are considered high-risk surgical candidates. This study aimed to detect the incidence, cause, and correlates of mortality in patients who were not eligible to participate in the TAVI study.
Methods
From April 2007 to July 2009, a cohort of 362 patients with severe AS were screened and did not meet the inclusion/exclusion criteria to participate in the TAVI trial. These patients were assigned into two groups: I—medical arm, 274 (75.7%) [treated medically: 97 (35.4%) or by balloon aortic valvuloplasty (BAV): 177 (64.6%)]; and II—surgical arm, 88 (24.3%). Clinical follow-up was obtained by telephone contact or office visit.
Methods
From April 2007 to July 2009, a cohort of 362 patients with severe AS were screened and did not meet the inclusion/exclusion criteria to participate in the TAVI trial. These patients were assigned into two groups: I—medical arm, 274 (75.7%) [treated medically: 97 (35.4%) or by balloon aortic valvuloplasty (BAV): 177 (64.6%)]; and II—surgical arm, 88 (24.3%). Clinical follow-up was obtained by telephone contact or office visit.